Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.

Bravo, Francisco; Macpherson, Jamie A; Slack, Emma; Patuto, Nicola; Cahenzli, Julia; McCoy, Kathy D.; Macpherson, Andrew J.; Juillerat, Pascal (2021). Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clinical and translational gastroenterology, 12(2), e00298. Wolters Kluwer Health 10.14309/ctg.0000000000000298

[img]
Preview
Text
ct9-12-e00298.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (537kB) | Preview

INTRODUCTION

The development of biomarkers to guide management of anti-tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNFα agent infliximab (IFX).

METHODS

Patients with IBD were classified according to the shedding of an L-selectin (CD62L) from the surface of their granulocytes in whole blood. CD62L shedding was quantified by flow cytometry before and after drug administration. A clinical data collection from June 2012 to August 2017 with blinded IFX management was aimed at validating the long-term predictive value of this test.

RESULTS

Among 33 patients with IBD (17 Crohn's disease and 5 ulcerative colitis), 22 were predicted functional responders (PFR) and 11 were predicted as nonresponders (NR) according to the in vitro test. Five years after study initiation, 72% of PFR were still treated with IFX (vs 27% in the NR group; P < 0.05), with a median time spent under IFX of 45 vs 12 months (P = 0.019), respectively. Thirty-five medicosurgical events occurred with a median time to first event of 3 vs 30 months (P = 0.023), respectively. Our assay was the best independent predictor of staying long term on IFX (P = 0.056).

DISCUSSION

An assay-based in vitro test for functional blockade of TNFα (CD62L shedding) provides an excellent long-term (at 3-5 years) independent predictor of durable use of IFX in patients with IBD. Testing patients could personalize decision making to significantly reduce costs and risk of adverse events and complications.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Gastroenterologie / Mukosale Immunologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Gastroenterologie / Mukosale Immunologie

UniBE Contributor:

Bravo, Francisco Damian; Slack, Emma; Patuto, Nicola; Cahenzli, Julia; McCoy, Kathleen; Macpherson, Andrew and Juillerat, Pascal

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2155-384X

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Rahel Fuhrer

Date Deposited:

20 Sep 2021 12:30

Last Modified:

26 Sep 2021 03:07

Publisher DOI:

10.14309/ctg.0000000000000298

PubMed ID:

33735154

BORIS DOI:

10.48350/159087

URI:

https://boris.unibe.ch/id/eprint/159087

Actions (login required)

Edit item Edit item
Provide Feedback